CA2092271A1 - Use of g-csf for treating taxol side-effects - Google Patents

Use of g-csf for treating taxol side-effects

Info

Publication number
CA2092271A1
CA2092271A1 CA002092271A CA2092271A CA2092271A1 CA 2092271 A1 CA2092271 A1 CA 2092271A1 CA 002092271 A CA002092271 A CA 002092271A CA 2092271 A CA2092271 A CA 2092271A CA 2092271 A1 CA2092271 A1 CA 2092271A1
Authority
CA
Canada
Prior art keywords
csf
effects
taxol
host
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002092271A
Other languages
French (fr)
Other versions
CA2092271C (en
Inventor
Eddie Reed
Elise Kohn
Gisele Sarosy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of CA2092271A1 publication Critical patent/CA2092271A1/en
Application granted granted Critical
Publication of CA2092271C publication Critical patent/CA2092271C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Abstract

A method of treating a host using taxol comprising administering granulocyte colony-stimulating factor to the host being treated with taxol. The present inventive method allows for increased levels of taxol to be administered to the host in the treatment of various conditions, particularly with respect to ovarian tumors.
CA002092271A 1993-03-09 1993-03-23 Use of g-csf for treating taxol side-effects Expired - Lifetime CA2092271C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2841193A 1993-03-09 1993-03-09
US08/028,411 1993-03-09

Publications (2)

Publication Number Publication Date
CA2092271A1 true CA2092271A1 (en) 1994-09-10
CA2092271C CA2092271C (en) 2009-10-13

Family

ID=21843309

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002092271A Expired - Lifetime CA2092271C (en) 1993-03-09 1993-03-23 Use of g-csf for treating taxol side-effects

Country Status (2)

Country Link
US (1) US5496804A (en)
CA (1) CA2092271C (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5886026A (en) * 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030087954A1 (en) * 1997-01-07 2003-05-08 Sonus Pharmaceuticals, Inc. Method of treating bladder carcinoma using a Taxane/Tocopherol formulation
US6727280B2 (en) * 1997-01-07 2004-04-27 Sonus Pharmaceuticals, Inc. Method for treating colorectal carcinoma using a taxane/tocopherol formulation
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US20030105156A1 (en) * 1997-01-07 2003-06-05 Nagesh Palepu Method for administration of a taxane/tocopherol formulation to enhance taxane therapeutic utility
US5916903A (en) * 1997-02-28 1999-06-29 Synapse Pahrmaceuticals International, Inc. Method for reducing the effects of antineoplastic disease treatment
AU2214199A (en) * 1998-01-07 1999-07-26 Jenner Biotherapies, Inc. Therapeutic liposome-encapsulated immunomodulators
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
PL201329B1 (en) * 1998-02-05 2009-03-31 Novartis Ag Organic compounds containing compositions
US6194181B1 (en) * 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
US6121029A (en) 1998-06-18 2000-09-19 Novartis Ag Genes for the biosynthesis of epothilones
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
NZ527046A (en) 2001-01-16 2005-06-24 Vascular Therapies Llc A flexible cylindrical matrix material, preferably collagen with an antiproliferative agent preferably rapamycin dispersed throughout for implantation to be in contact with a vascular structure
US7442370B2 (en) * 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
DE10105509A1 (en) * 2001-02-07 2002-08-14 Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh New ice-lollipop for treating oral mucositis comprises herbal extracts to give additional therapeutic effects
US7276580B2 (en) * 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
AU2002250203B2 (en) 2001-03-28 2006-08-10 Biogen Ma Inc. Use of neublastin polypeptides for treating neuropathic pain
CZ294371B6 (en) * 2002-06-10 2004-12-15 Pliva - Lachema, A. S. Stabilized pharmaceutical composition based on polyoxyethylated castor oil and process for preparing thereof
US20040047835A1 (en) * 2002-09-06 2004-03-11 Cell Therapeutics, Inc. Combinatorial drug therapy using polymer drug conjugates
JP4571776B2 (en) * 2002-11-05 2010-10-27 Ｊｘ日鉱日石エネルギー株式会社 Lubricating oil composition
US7695723B2 (en) * 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
RS52910B (en) 2003-01-31 2014-02-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
ATE433759T1 (en) 2003-04-18 2009-07-15 Biogen Idec Inc POLYMER CONJUGATED GLYCOSILATED NEUBLASTIN
WO2005034986A1 (en) * 2003-10-14 2005-04-21 Chugai Seiyaku Kabushiki Kaisha Remedy for kidney diseases
CA2577755C (en) * 2004-08-19 2014-05-13 Biogen Idec Ma Inc. Neublastin variants
JP4959566B2 (en) * 2004-08-19 2012-06-27 バイオジェン・アイデック・エムエイ・インコーポレイテッド Folding of transforming growth factor β family proteins
WO2006114115A1 (en) * 2005-04-26 2006-11-02 Trion Pharma Gmbh Combination of antibodies and glucocorticoids for treating cancer
TWI501774B (en) * 2006-02-27 2015-10-01 Biogen Idec Inc Treatments for neurological disorders
US20100056440A1 (en) * 2006-03-01 2010-03-04 Biogen Idec Ma Inc. Compositions and methods for administering gdnf ligand family proteins
US8329655B2 (en) * 2007-05-01 2012-12-11 Biogen Idec Ma Inc. Methods for increasing vascularization
EP2205634A2 (en) * 2007-08-08 2010-07-14 Biogen Idec MA, Inc. Anti-neublastin antibodies and uses thereof
EP2358199A2 (en) * 2008-11-02 2011-08-24 Optimata Ltd. Improving cancer therapy by docetaxel and granulocyte colony-stimulating factor (g-csf)
JP2012520314A (en) 2009-03-11 2012-09-06 アムビト ビオスシエンセス コルポラチオン Combination of indazolylaminopyrrolotriazine and taxane for cancer treatment
RU2488890C1 (en) * 2012-02-24 2013-07-27 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук Method for simulating chronic cytostatic myelosuppression

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1289880C (en) * 1985-12-06 1991-10-01 Jeffrey L. Winkelhake Anti-human ovarian cancer immunotoxins and methods of use thereof
US4961926A (en) * 1987-11-19 1990-10-09 Sloan-Kettering Institute For Cancer Research Methods for prevention and treatment of mucositis with granulocyte colony stimulating factor
US4942184A (en) * 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
US5157049A (en) * 1988-03-07 1992-10-20 The United States Of America As Represented By The Department Of Health & Human Services Method of treating cancers sensitive to treatment with water soluble derivatives of taxol
US5104651A (en) * 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5886026A (en) * 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use

Also Published As

Publication number Publication date
US5496804A (en) 1996-03-05
CA2092271C (en) 2009-10-13

Similar Documents

Publication Publication Date Title
CA2092271A1 (en) Use of g-csf for treating taxol side-effects
CA2119006A1 (en) Composition and method of treating hepatitis c
GR3032511T3 (en) Combination with anti-hormonal compounds and binding molecules for the treatment of cancer.
CA2083179A1 (en) Isoxazole-4-carboxamides and hydroxyalkylidenecyanoacetamides, pharmaceuticals containing these compounds and their use
CA2265547A1 (en) Method of treating endothelial injury
AU6875694A (en) A wood preservative composition, process for treating wood with the same, and wood treated with the same
CA2117891A1 (en) Method of treating cancer by conjunctive therapy with 2'-halomethylidene derivatives and an s-phase or m-phase specific antineoplastic agent
PL323798A1 (en) Application of derivatives of vitamin d4 in treating skin diseases
CA2281807A1 (en) Method of treating a tumor
AU628095B2 (en) Chelants possessing ortho ligating functionality and complexes thereof
BR9500436A (en) Products use of a g-csf use of a tnf protein ligand process for the treatment and / or prevention of septic shock
AU3245489A (en) Pharmaceutical compositions with anti-cancer activity and method for the treatment of cancer
EP0281070A3 (en) Pharmaceutical composition for the treatment of cancer
ES2120962T3 (en) ANTIVIRICA COMPOSITION.
EP0325129A3 (en) Disubstituted pyridines
DE3685484D1 (en)
GR3021813T3 (en) Method of treating alopecia
ZA957506B (en) L-carnite salt and cosmetic and pharmaceutical compositions containing same for treating dermatoses
MY122052A (en) Method of treating tourette''s syndrome
CA2081911A1 (en) Method and composition for treating psoriasis
DE68916777T2 (en) Use of TNF for the manufacture of a medicament for the treatment of psoriasis.
WO2002076393A3 (en) Antiagionecic, antitumor, chemopreventative agents
CA2103707A1 (en) Treatment of non-small cell lung carcinoma
AU7719491A (en) Therapeutic compound
CA2103708A1 (en) Treatment of ovarian cancer

Legal Events

Date Code Title Description
EEER Examination request